Observational Study of the Use of Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting in Austria, Germany and Switzerland
Status: Recruiting
Location: See all (70) locations...
Study Type: Observational
SUMMARY
An observational study to assess the effectiveness, health economic-relevant costs and participant reported outcomes in participants with Chronic lymphocytic leukemia (CLL) receiving venetoclax as a monotherapy or in combination with rituximab, obinutuzumab, ibrutinib, or acalabrutinib as prescribed at the discretion of the physician and in accordance with local clinical practice and label.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• \- Participant with chronic lymphocytic leukemia (CLL) who start venetoclax therapy can be included in the study if treated as specified in the local label for any specific line of treatment.
Locations
Other Locations
Austria
Medizinische Universitaet Graz /ID# 221155
COMPLETED
Graz
Landeskrankenhaus Salzburg-Universitaetsklinikum der PMU (LKH) /ID# 221153
ACTIVE_NOT_RECRUITING
Salzburg
Universitaetsklinikum St. Poelten /ID# 221152
COMPLETED
Sankt Pölten
Hanusch Krankenhaus /ID# 221151
COMPLETED
Vienna
Germany
MVZ am Klinikum Aschaffenburg Onkologie /ID# 201548
COMPLETED
Aschaffenburg
Studienzentrum Aschaffenburg /ID# 204125
COMPLETED
Aschaffenburg
Gemeinschaftspraxis Dr. Heinrich und Prof. Bangerter /ID# 200950
COMPLETED
Augsburg
Praxis Dr. Kreher /ID# 202604
COMPLETED
Bad Liebenwerda
Caritas-Krankenhaus gGmbH /ID# 243212
COMPLETED
Bad Mergentheim
Drs. Tanzer, Chirca, Stoeberl /ID# 202613
COMPLETED
Bad Reichenhall
MVZ Klinikum Mittelbaden GmbH /ID# 206207
COMPLETED
Baden-baden
Onkologie am Segelfliegerdamm /ID# 202603
COMPLETED
Berlin
Onkologische Schwerpunktpraxis /ID# 200953
COMPLETED
Berlin
Praxis am Volkspark /ID# 243195
COMPLETED
Berlin
Praxis für Hämatologie und Onkologie /ID# 241763
COMPLETED
Berlin
Ambulantes Tumorzentrum Bremerhaven /ID# 224353
COMPLETED
Bremerhaven
Pioh Dres. Draube & Partner /ID# 239507
COMPLETED
Cologne
BAG Freiberg-Richter, Jacobasch, Illmer, Wolf /ID# 201532
COMPLETED
Dresden
Onkozentrum Dresden /ID# 202599
COMPLETED
Dresden
Praxis Dres. Prange-Krex/Mohm /ID# 210049
COMPLETED
Dresden
St. Georg Klinikum Eisenach gemeinnützige GmbH (GKE) /ID# 250200
COMPLETED
Eisenach
Internistische Schwerpunktpraxen, Erlangen /ID# 200949
COMPLETED
Erlangen
Praxis Dres. Kiehl/Stein /ID# 210052
COMPLETED
Frankfurt (oder)
Centrum fuer Haematologie und Onkologie Bethanien /ID# 206701
COMPLETED
Frankfurt Am Main
Klinikum Frankfurt Hoechst /ID# 210048
COMPLETED
Frankfurt Am Main
MVZ Dres. Cordes & Partner /ID# 202598
COMPLETED
Frankfurt Am Main
Praxis fuer interdisziplinaere Onkolologie und Haematologie /ID# 206999
COMPLETED
Freiburg Im Breisgau
Onkologische Kooperation Harz /ID# 201550
COMPLETED
Goslar
MVZ Onkologie GmbH /ID# 212376
COMPLETED
Hagen
Evidia MVZ III Oncology Halle /ID# 218354
COMPLETED
Halle
OncoResearch Lerchenfeld GmbH /ID# 205237
COMPLETED
Hamburg
Onkologische Gemeinschaftspraxis /ID# 205239
COMPLETED
Hamburg
Evangelisches Krankenhaus Hamm /ID# 206703
COMPLETED
Hamm
OAZ Hannover /ID# 201538
COMPLETED
Hanover
Studienbüro Kamal und Dorn GBR /ID# 234105
COMPLETED
Hanover
Studienzentrum am Raschplatz /ID# 250180
COMPLETED
Hanover
Onkologie Hof /ID# 201531
COMPLETED
Hof
Klinikum Idar-Oberstein GmbH /ID# 210046
COMPLETED
Idar-oberstein
Hämatologie und Onkologie /ID# 205247
COMPLETED
Kaiserslautern
Praxis Dres. Tebbe/Mayer /ID# 206730
COMPLETED
Kassel
Praxis Dr. Stauch /ID# 202611
COMPLETED
Kronach
VK&K Studien GbR /ID# 202614
COMPLETED
Landshut
Praxis Fuchs/Koehler /ID# 243215
COMPLETED
Langenhessen
Luebecker Oncology Practice /ID# 200952
COMPLETED
Lübeck
Haemato-Onkologie /ID# 205236
COMPLETED
Munich
Stauferklinikum Schwaebisch Gmuend /ID# 201518
COMPLETED
Mutlangen
Friedrich-Ebert-Krankenhaus GmbH /ID# 206206
COMPLETED
Neumünster
Praxis Dr. Klaproth/Cura /ID# 216413
COMPLETED
Neunkirchen
Praxis Dres. Plewe/Losem /ID# 202606
COMPLETED
Neuss
Onkolologische Praxis Oldenburg /ID# 202607
COMPLETED
Oldenburg
MVZ der Paracelsus-Klinik /ID# 201541
COMPLETED
Osnabrück
Bruederkrankenhaus St. Josef Paderborn /ID# 202600
COMPLETED
Paderborn
Onkologische Praxis GbR /ID# 206705
COMPLETED
Porta Westfalica
MVZ f. Blut- u.Krebserkrankungen /ID# 206704
COMPLETED
Potsdam
Praxis Dres. Krober/Stosiek /ID# 206729
COMPLETED
Regensburg
Praxis Dres. Decker/Lakner/Leithäuser /ID# 206208
COMPLETED
Rostock
Diakonieklinikum Schwaebisch Hall /ID# 206205
COMPLETED
Schwäbisch Hall
MVZ am Schlossgarten GmbH /ID# 210043
COMPLETED
Schwetzingen
Onkologische Praxis /ID# 201545
COMPLETED
Stuttgart
Schwarzwald-Baar-Klinikum /ID# 208176
COMPLETED
Villingen-schwenningen
Med. Studiengesellschaft Nord West GmbH /ID# 201535
COMPLETED
Westerstede
Switzerland
Kantonsspital Aarau AG /ID# 210034
COMPLETED
Aarau
EOC Ospedale Regionale di Bellinzona e Valli /ID# 208782
COMPLETED
Bellinzona
Inselspital, Universitaetsspital Bern /ID# 210031
COMPLETED
Bern
Luzerner Kantonsspital /ID# 210029
COMPLETED
Lucerne
Kantonsspital Münsterlingen /ID# 210035
COMPLETED
Münsterlingen
Réseau Hospitalier Neuchâtelois /ID# 227865
RECRUITING
Neuchâtel
Kantonsspital St. Gallen /ID# 223037
COMPLETED
Sankt Gallen
Spital Thun /ID# 233714
COMPLETED
Thun
KSW Kantonsspital Winterthur /ID# 211068
COMPLETED
Winterthur
Contact Information
Primary
Johannes Huelsenbeck
johannes.huelsenbeck@abbvie.com
+49 611-1720-3036
Backup
Stefan Lorenz
stefan.lorenz@abbvie.com
Time Frame
Start Date: 2017-12-04
Estimated Completion Date: 2030-12
Participants
Target number of participants: 500
Treatments
Participants Receiving Venetoclax
Participants with Chronic Lymphocytic Leukemia (CLL) receiving venetoclax.
Participants Receiving Venetoclax + Rituximab
Participants with CLL receiving venetoclax in combination with rituximab.
Participants Receiving Venetoclax + Obinutuzumab
Participants with CLL receiving venetoclax in combination with obinutuzumab.
Participants Receiving Venetoclax + Ibrutinib
Participants with CLL receiving venetoclax in combination with ibrutinib.
Participants Receiving Venetoclax + Acalabrutinib
Participants with CLL receiving venetoclax in combination with acalabrutinib.
Related Therapeutic Areas
Sponsors
Leads: AbbVie